Ceftazidime-avibactam

Where the papers sit

9 papers from the last 6 months study ceftazidime-avibactam directly · updated from PubMed 8 Oct 2026

• KPC Variant Emergence

  Ceftazidime-avibactam pressure is selecting diverse KPC variants in Klebsiella pneumoniae, including KPC-25, KPC-127 and KPC-33. These variants recur in intracranial infection, ICU outbreaks and ST11 or ST307 lineages, but show heterogeneous fitness. Whole-genome sequencing and in vitro evolution connect resistance with altered KPC enzymes and, in some isolates, a mutHV76G-associated hypermutator phenotype. Cefiderocol and mutant-prevention strategies are being explored as alternatives, while treatment management remains unsettled.

  5 papers · 55.6%

• Real-World Treatment Outcomes

  Ceftazidime-avibactam is being evaluated as a practical treatment for multidrug-resistant gram-negative pneumonia, carbapenem-resistant Enterobacterales bacteremia and other severe infections. The recurring clinical questions are whether earlier initiation improves outcomes and how effectiveness varies with septic shock, acute kidney injury and serum albumin. Data from large multicenter and Korean retrospective cohorts support use in high-risk infections but do not establish a uniform timing advantage. Observational design and heterogeneous populations remain the main limitations.

  3 papers · 33.3%

• OXA-1381-Mediated Resistance

  OXA-1381, particularly the W157L Ω-loop variant, is emerging as a mechanism of ceftazidime-avibactam resistance in Pseudomonas aeruginosa. The work links this beta-lactamase change to in vivo treatment failure and examines its effects on related agents. Meropenem and ceftolozane-tazobactam provide clinical context but are not consistent solutions. The main unresolved issue is how often this mechanism arises and how best to detect and treat it.

  1 papers · 11.1%